🇺🇸 FDA
Pipeline program

Gatifloxacin 0.3% ophthalmic solution

198782-002

Phase 2 small_molecule completed

Quick answer

Gatifloxacin 0.3% ophthalmic solution for Acute Bacterial Corneal Ulcers is a Phase 2 program (small_molecule) at Allergan Pharmaceuticals International Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Allergan Pharmaceuticals International Limited
Indication
Acute Bacterial Corneal Ulcers
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials